Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
Recently, we reported on potent EphA2 targeting compounds and demonstrated that dimeric versions of such agents can exhibit remarkably increased agonistic activity in cellular assays compared to the monomers. Here we further characterize the activity of dimeric compounds at the structural, biochemic...
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
MDPI AG
2020-05-01
|
| Seri Bilgileri: | Pharmaceuticals |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1424-8247/13/5/90 |